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OBJECTIVE—Amino acids stimulate glucagon responses to
hypoglycemia and may be utilized by the brain. The aim of this
study was to assess the responses to hypoglycemia in non-
diabetic and type 1 diabetic subjects after ingestion of an amino
acid mixture.
RESEARCH DESIGN AND METHODS—Ten nondiabetic and
10 diabetic type 1 subjects were studied on three different
occasions during intravenous insulin (2 mU  kg
1  min
1) plus
variable glucose for 160 min. In two studies, clamped hypo-
glycemia (47 mg/dl plasma glucose for 40 min) was induced and
either oral placebo or an amino acid mixture (42 g) was given at
30 min. In the third study, amino acids were given, but euglyce-
mia was maintained.
RESULTS—Plasma glucose and insulin were no different in the
hypoglycemia studies with both placebo and amino acids (P 
0.2). After the amino acid mixture, plasma amino acid concen-
trations increased to levels observed after a mixed meal (2.4 
0.13 vs. placebo study 1.7  0.1 mmol/l, P  0.02). During
clamped euglycemia, ingestion of amino acids resulted in tran-
sient increases in glucagon concentrations, which returned to
basal by the end of the study. During clamped hypoglycemia,
glucagon response was sustained and increased more in amino
acid studies versus placebo in nondiabetic and diabetic subjects
(P  0.05), but other counter-regulatory hormones and total
symptom score were not different. -OH-butyrate was less sup-
pressed after amino acids (200  15 vs. 93  9 mol/l, P  0.01).
Among the cognitive tests administered, the following indicated
less deterioration after amino acids than placebo: Trail-Making
part B, PASAT (Paced Auditory Serial Addition Test) (2 s), digit
span forward, Stroop colored words, and verbal memory tests for
nondiabetic subjects; and Trail-Making part B, digit span back-
ward, and Stroop color tests for diabetic subjects.
CONCLUSIONS—Oral amino acids improve cognitive function
in response to hypoglycemia and enhance the response of
glucagon in nondiabetic and diabetic subjects. Diabetes 57:
1905–1917, 2008
I
n type 1 diabetes, there is not only failure of the
pancreatic -cell but also severe impairment of the
-cell in terms of response to hypoglycemia (1,2).
Adequate glucagon secretory response to falling
plasma glucose concentration, which, along with adrena-
line response, is normally the primary line of defense
against hypoglycemia (3), is lost within a few months of
diabetes onset (2). This process appears unavoidable,
irreversible, and unrecoverable in the natural history of
the disease (4), contributing to impaired glucose counter-
regulation and risk of severe hypoglycemia (5). As a result,
in type 1 diabetes, the therapeutic goal of near-normogly-
cemia with intensive insulin treatment may carry the
burden of greater frequency of hypoglycemia, as indicated
by the Diabetes Control and Complications Trial (6).
Several attempts have been made to reduce the risk of
hypoglycemia in intensively treated type 1 diabetes. The
efforts have been substantially focused in two directions.
The ﬁrst has been to deﬁne more rational and physiologi-
cal strategies of insulin replacement (7–9). The second has
been to explore the possibility of inducing a recovery of
glucagon response to hypoglycemia. The ﬁnding that a
number of amino acids may stimulate glucagon release
from pancreatic -cells (10) has prompted a series of
studies to test the hypothesis that amino acid stimulation
may sustain glucagon secretion in response to hypoglyce-
mia in type 1 diabetes (11–13). The majority of studies
have been conducted by giving amino acids intravenously
as a mixture (11), as dipeptide (alanine and glutamine)
(12), or as a single amino acid (alanine) (13), with con-
ﬂicting results. Our group has recently shown that intra-
venous alanine is able to partially restore glucagon
response to insulin-induced hypoglycemia (13). Surpris-
ingly, to the best of our knowledge, no study so far has
examined whether amino acids given orally may stimulate
glucagon response during insulin-induced hypoglycemia in
type 1 diabetes. This hypothesis might be interesting,
because previous studies have shown that the failure of
glucagon response to hypoglycemia in type 1 diabetes
recovers after food intake (14,15). This has led to the
hypothesis that it is the protein component of the meal
that induces such an effect (15). In fact, oral alanine may
improve glucose recovery from hypoglycemia mediated by
a sustained increase in plasma glucagon in type 1 diabetes
(16,17). In addition to the potential effect on recovery of
glucagon responses, amino acids might also serve as a
substrate alternative to glucose for the brain and therefore
limit cognitive dysfunction during hypoglycemia (18), as
do lactate (19) and -hydroxybutyrate (20).
The aim of the present study was to examine the effects
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hormonal counterregulatory responses, particularly gluca-
gon, and responses of symptoms and cognitive function
during insulin-induced hypoglycemia in people with type 1
diabetes compared with nondiabetic subjects.
RESEARCH DESIGN AND METHODS
Institutional review board approval was obtained for these studies. Ten
healthy nondiabetic volunteers (5 men, age 32  7 years, BMI 23  2 kg/m
2,
C-peptide 1.2  0.2 nmol/l, A1C 4.6  0.3% [means  SD]) were studied along
with 10 subjects with type 1 diabetes on long-term intensive insulin treatment
(6 men, age 30  8 years, diabetes duration 17  7.8 years, BMI 22.7  1.8
kg/m
2, A1C 7.4  1.0% [means  SD]). At the time of the study, all type 1
diabetic subjects were free of any detectable microangiopathic complication
and were negative at the screening for autonomic neuropathy, as judged on
the basis of a standard battery of cardiovascular tests (21).
The study was carried out according to the Declaration of Helsinki after
obtaining written informed consent from all subjects. All nondiabetic and
diabetic volunteers were studied on three different occasions in a random,
computer-generated sequence at 2- to 3-week intervals with the modiﬁed
hyperinsulinemic glucose clamp technique used to either maintain euglycemia
or induce hypoglycemia. In diabetic subjects, care was taken to avoid
preprandial, postprandial, and nocturnal blood glucose 72 mg/dl over the
week before studies as previously reported (22). Brieﬂy, the glycemic targets
were blood glucose 110–130 mg/dl in the fasting state, before meals, and at
bedtime, and blood glucose 140–180 mg/dl 2 h after meals. Blood glucose was
measured in the fasting state, before meals, and 2 h after meals and three
times a week at 0300 h. In addition, blood glucose was measured whenever
subjects believed their sugar was low. Patients were advised to decrease or
increase the dose of basal insulin if their fasting blood glucose was repeatedly
110 mg/dl or 130 mg/dl, and to decrease or increase the dose of rapid-
acting insulin at meals if their 2-h postprandial blood glucose was repeatedly
140 mg/dl or 180 mg/dl. Adjustments of rapid-acting insulin dose were
made according to the carbohydrate content of meals. Four subjects had six
values of blood glucose between 55 and 72 mg/dl in the week before the study,
which caused the postponing of the study to the next week. Finally, to avoid
hypoglycemia the day before the experiment, the total daily insulin dosage
was cut by 20%, and patients were asked to contact one investigator by phone
to receive advice on insulin doses.
On the morning of the studies, all nondiabetic and diabetic subjects were
admitted to the General Clinical Research Center of the Department of
Internal Medicine at 	0700 h. A hand vein of the nondominant arm was
cannulated retrogradely and maintained in a hot box (	60°C) for sampling of
arterialized-venous blood (23). A superﬁcial vein of the ipsilateral arm was
also cannulated for infusion of insulin and glucose (see below). The two veins
were maintained patent by means of 0.9% NaCl infusion (0.5 ml/min). In the
diabetic subjects, an intravenous infusion of human regular insulin (diluted to
1 unit/ml in 2 ml of the subject’s blood and 0.9% NaCl to a ﬁnal volume of 100
ml) was begun at 	0730 h in a feedback fashion, using a syringe pump
(Harvard Apparatus, Ealing, South Natick, MA), according to an algorithm
described previously (24), to reach the target plasma glucose of 100 mg/dl by
0830 h.
In all studies at time 0900 h (time 0 min), in both nondiabetic and diabetic
subjects, intravenous insulin at the rate of 2 mU  kg
1  min
1 was started and
continued until the end of the study (i.e., 160 min). Intravenous glucose at
variable rate was also infused to maintain euglycemia (plasma glucose at 90
mg/dl) throughout the study on one occasion (clamped euglycemic study),
whereas on the other two occasions, the rate of glucose infusion was
decreased after 30 min to allow plasma glucose to fall and reach the target
plasma glucose of 47 mg/dl at 120 min. This hypoglycemic plateau was
maintained for the next 40 min, that is, until the end of the study (clamped
hypoglycemic studies).
On each occasion, at 30 min, subjects ingested over a 5-min period a 200-ml
drink containing either a mixture of amino acids (3.1 g lysine, 1.7 g histidine,
3.1 g arginine, 2.8 g aspartate, 2.3 g threonine, 2 g serine, 1 g glutamate, 3.3 g
proline, 2.7 g glycine, 1.7 g alanine, 1.1 g cysteine, 3 g valine, 0.7 g methionine,
2.7 g isoleucine, 4.6 g leucine, 4.1 g tyrosine, 0.5 g phenylalanine, 0.9 g
tryptophan, and 2.1 g glutamine) or a seemingly identical placebo rendered
palatable by ﬂavoring it with artiﬁcial fruit ﬂavor and adding 2 g sucrose and
1 g aspartame. All drinks were prepared and administered by a research nurse
not involved in the further execution of the study. The mixture of amino acids
was given both in the clamped euglycemia study (euglycemia–amino acid
study) and in one of the two clamped hypoglycemia studies (hypoglycemia–
amino acid study), whereas in the other clamped hypoglycemia study subjects
ingested placebo (hypoglycemia-placebo study).
In all studies, blood samples were drawn at 5- to 10-min intervals for
bedside plasma glucose measurement and at 30-min intervals for measure-
ment of plasma insulin, C-peptide, pancreatic polypeptide, amino acid, coun-
terregulatory hormone, and nonglucose substrate concentration (see below).
A semiquantitative symptom questionnaire (25) was administered every 30
min. Subjects were asked to score from 0 (none) to 5 (severe) on each of the
following symptoms: seven autonomic/neurogenic (adrenergic: heart pound-
ing, tremor, anxiety, and irritability; cholinergic: sweating, hunger, and
tingling); ﬁve neuroglycopenic (difﬁculty in thinking, weakness, dizziness,
blurred vision, and drowsiness); and three nonspeciﬁc (thirst, nausea, and
headache) (26). The sum of each of these constituted the total symptom score.
In addition, at baseline, before inducing hypoglycemia, and at the hypogly-
cemic plateau (indicated as “time 30,” “time 0,” and “time 120,” respectively)
and at similar times during the euglycemic studies, cognitive function was
assessed by applying a battery of hypoglycemia-sensitive tests: Trail-Making
parts A and B (27); verbal ﬂuency (28); verbal memory (28); digit vigilance
(28); forward and backward digit span (29); Stroop word, color, and color-
word (interference) subtests (30); and the Paced Auditory Serial Addition Test
(PASAT; 2 and 3 s) (31). Tests were always performed in this order.
Analytical methods. Plasma glucose was measured by means of a Beckman
glucose analyzer (Glucose Analyzer II; Beckman Instruments, Fullerton, CA).
Plasma insulin, C-peptide, pancreatic polypeptide, counterregulatory hor-
mone, glucagon, adrenaline, norepinephrine, glycerol, -OH-butyrate, lactate,
and alanine were measured by previously described assays (32). Plasma
concentrations of amino acids were measured by high-performance liquid
chromatography with postcolumn o-phalaldehyde derivatization (33). To
remove antibody-bound insulin, plasma was mixed with an equal volume of
30% polyethylene glycol immediately after blood collection in both type 1
diabetic and nondiabetic subjects (34). A1C was determined by high-perfor-
mance liquid chromatography using a Hi-AUTO A1C, TM HA 8121 apparatus
(DIC; Kyoto Daiichi, Kogaku, Japan). Plasma free fatty acid (FFA) concentra-
tions were measured using a commercial kit (Wako NEFA C test kit; Wako
Chemicals, Neuss, Germany).
Statistical analysis. All data were subjected to repeated-measures ANOVA
with Huynh-Feldt adjustment for nonsphericity (35). The ANOVA model
included the sequence of studies as the between-subjects factor, whereas
test condition (hypoglycemia-placebo/hypoglycemia–amino acid/euglycemia–
amino acid) and time were the within-subjects factors. Subjects were entered
into the model as random factors. The factor group (nondiabetic/diabetic
subjects) was entered into the model as a between-subjects factor. If there
were signiﬁcant differences between baseline values, these were used as
covariates. In this way, the data over the serial time points could be adjusted
for any differences in baseline values (35). Post hoc comparisons (Newman-
Keuls test) were carried out to pinpoint speciﬁc differences on signiﬁcant
interaction terms.
The area under the curves (AUCs) for counterregulatory hormones and
substrates at the clamped hypoglycemia period (120–160 min) were calcu-
lated according to the trapezoidal rule. The incremental AUC (iAUC) for
glucagon response was calculated by subtracting plasma glucagon values
before amino acid ingestion from the total AUC.
A modiﬁed Bonferroni procedure (36) for multiple cognitive test adjust-
ments was used to maintain an overall type 1 error rate of 5% (0.05).
Data are given as means  SE, except where SD is speciﬁed. We
considered differences to be statistically signiﬁcant if the P value was 0.05 or
less. We conducted the statistical analyses by using NCSS 2007 software
(Kaysville, UT) and Statistica software, version 6.0 (StatSoft, Tulsa, OK).
RESULTS
Plasma glucose and insulin concentrations and rates
of glucose infusion (Fig. 1). In all study conditions,
plasma glucose was maintained at the preselected pla-
teaus, with no differences between groups and study
conditions (P  0.2).
Plasma insulin concentrations achieved during the study
did not differ between nondiabetic and diabetic subjects or
in relation to treatment conditions. On average, baseline
plasma insulin concentrations were lower in nondiabetic
compared with diabetic subjects (P  0.001) in all study
conditions.
The rates of glucose infusion were lower during the
hypoglycemia plateau in the hypoglycemia–amino acid
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mia–amino acid studies in nondiabetic subjects (2.6  0.4
vs. 5.5  0.6 and 8.8  0.9 mg  kg
1  min
1, respectively,
P  0.001) and in diabetic subjects (3.1  0.7 vs. 5.4  0.5
and 9.4  0.9 mg  kg
1  min
1, respectively, P  0.001).
Glucose infusion rates were not different between non-
diabetic and diabetic subjects (P  0.661).
Plasma glucagon, C-peptide, and pancreatic polypep-
tide concentrations. Plasma glucagon concentrations
were similar at baseline in nondiabetic and diabetic
subjects in all study conditions. In the hypoglycemia-
placebo study, plasma glucagon concentrations after an
initial decrease at 60 min increased (P  0.001) in
nondiabetic subjects, whereas it did not increase in
diabetic subjects (P  0.867). The ingestion of amino
acids in the hypoglycemia–amino acid study increased
signiﬁcantly the response of glucagon to hypoglycemia
in nondiabetic and, to a lesser extent, in diabetic
subjects compared with the hypoglycemia-placebo
study (Table 1). Amino acids stimulated glucagon re-
sponse also in the euglycemia–amino acid study, which
was maximal between 75–120 min and then tended to
decrease to baseline values at 120–160 min. In diabetic
subjects, the response of glucagon to hypoglycemia
stimulated by amino acids was lower than that of
nondiabetic subjects. However, it was superimposable
on that of nondiabetic subjects in the hypoglycemia-
placebo study (P  0.581; Table 1). Interestingly, al-
though the iAUC of glucagon response in the
hypoglycemia–amino acid study was 4.7 times greater in
nondiabetic compared with diabetic subjects (7,468 
835 and 1,599  142 ng/l, respectively, P  0.001), the
estimated contribution of amino acids per se in directly
stimulating glucagon secretion, as derived from the
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FIG. 1. Plasma glucose and free insulin concentrations and rates of glucose infusion during clamped euglycemia with amino acid (F) ingestion and
clamped hypoglycemia both with placebo (E) and amino acid (Œ) ingestion in 10 nondiabetic (left) and 10 type 1 diabetic (right) subjects.
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1908 DIABETES, VOL. 57, JULY 2008euglycemia–amino acid study, was not statistically dif-
ferent in both nondiabetic and diabetic subjects (19  4
and 35  7%, respectively, P  0.061).
Plasma C-peptide concentrations in nondiabetic sub-
jects decreased at 30 min in all studies and then remained
suppressed in the hypoglycemia-placebo study, whereas
they increased after the ingestion of amino acids more in
the euglycemia–amino acid than in the hypoglycemia–
amino acid study (P  0.05, Fig. 2). By the end of the study,
however, C-peptide concentrations returned to basal val-
ues and were suppressed in the euglycemia–amino acid
and hypoglycemia–amino acid studies, respectively.
Plasma C-peptide concentrations were undetectable in
diabetic subjects in all studies.
Plasma pancreatic polypeptide concentration increased
during hypoglycemia-placebo and hypoglycemia–amino
acid studies in both nondiabetic and diabetic subjects,
although the peak response was higher in the hypo-
glycemia–amino acid study in nondiabetic subjects but
not in diabetic subjects (Table 1). Pancreatic polypep-
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DIABETES, VOL. 57, JULY 2008 1909tide levels did not change in euglycemia–amino acid
studies.
Plasma adrenaline, norepinephrine, cortisol, and
growth hormone concentrations. Plasma adrenaline
levels increased in the hypoglycemia-placebo and hypogly-
cemia–amino acid studies in both nondiabetic and diabetic
subjects. However, responses were lower in diabetic com-
pared with nondiabetic subjects (Table 1; P  0.05). In the
euglycemia–amino acid study, adrenaline levels did not
change compared with basal values in both groups (Table
1).
Plasma norepinephrine concentrations were not differ-
ent in all study conditions in both nondiabetic and diabetic
subjects (Table 1; P  0.2).
Responses of plasma cortisol and growth hormone
increased similarly in response to hypoglycemia-placebo
and hypoglycemia–amino acid compared with euglycemi-
a–amino acid in both nondiabetic and diabetic subjects
(Fig. 3; Table 1).
Plasma nonglucose substrate (Fig. 4). Plasma FFA
levels decreased similarly in all studies in both nondiabetic
and diabetic subjects. However, FFA concentrations at
120–160 min were higher in the hypoglycemia-placebo and
hypoglycemia–amino acid compared with euglycemia–
amino acid studies (P  0.018) in nondiabetic subjects.
They were not different in diabetic subjects (P  0.712).
Plasma glycerol concentrations decreased from basal
values in all studies in both nondiabetic and diabetic
subjects. However, similar to FFA, glycerol levels were
higher in the hypoglycemia-placebo and hypoglycemia–
amino acid compared with euglycemia–amino acid studies
(P  0.018) only in nondiabetic subjects.
Plasma -OH-butyrate concentrations, after an initial
decrease to nadir values at 90 and 60 min in nondiabetic
and diabetic subjects, respectively, increased in the hypo-
glycemia–amino acid and euglycemia–amino acid but not
in the hypoglycemia-placebo studies in both nondiabetic
(P  0.001) and diabetic subjects (P  001).
Plasma lactate concentrations increased in all studies in
both nondiabetic and diabetic subjects. In nondiabetic
subjects, plasma lactate increased more in the hypoglyce-
mia-placebo compared with both the hypoglycemia–amino
acid (P  0.025) and the euglycemia–amino acid (P 
0.008) studies. In diabetic subjects, lactate was similar in
the hypoglycemia-placebo, hypoglycemia–amino acid, and
euglycemia–amino acid studies (P  0.2). Overall, plasma
lactate response in nondiabetic was greater than that of
diabetic subjects (nondiabetic vs. diabetic subjects: hypo-
glycemia-placebo, P  0.001; hypoglycemia–amino acid,
P  0.005; and euglycemia–amino acid, P  0.046).
Plasma branched and nonbranched chain amino acid
concentrations. Branched and nonbranched chain amino
acid (BCAA and N-BCAA, respectively) concentrations
were similar at baseline in nondiabetic and diabetic sub-
jects in all studies (Fig. 5). After the ingestion of amino
acids, both BCAA and N-BCAA levels increased similarly
in the hypoglycemia–amino acid and euglycemia–amino
acid studies. In the hypoglycemia-placebo studies, both
BCCA and N-BCCA concentrations tended to decrease
from basal values by the end of study with no difference
between the two groups (Fig. 5).
Symptoms. The score of autonomic and neuroglycopenic
symptoms increased in the hypoglycemia-placebo and
hypoglycemia–amino acid studies with no difference (P 
0.2) between studies in both nondiabetic and diabetic
subjects, whereas it did not change in the euglycemia–
amino acid studies in nondiabetic and diabetic subjects
(Fig. 6).
Cognitive function. With the exception of Trail-Making
part A, digit vigilance, and Stroop words and colors tests in
nondiabetic subjects and of Trail-Making part A and digit
vigilance tests in diabetic subjects, all cognitive tests
deteriorated signiﬁcantly during hypoglycemia compared
with euglycemia–amino acid, in both hypoglycemia-pla-
cebo and hypoglycemia–amino acid (Table 2). However,
the degree of deterioration was lower in hypoglycemia–
amino acid than in hypoglycemia-placebo in the following
tests: Trail-Making part B, PASAT (2 s), digit span forward,
and Stroop colored words and verbal memory tests in
nondiabetic subjects and Trail-Making part B, digit span
backwards, and Stroop color tests in diabetic subjects.
DISCUSSION
The present study was undertaken to examine the effects
of the ingestion of a mixture of amino acids on the
counterregulatory, symptomatic, and cognitive responses
to hypoglycemia. Both nondiabetic and type 1 diabetic
subjects were studied. First, the results indicate that oral
amino acids enhance glucagon response to hypoglycemia
in both nondiabetic and diabetic subjects, although to a
lesser extent in the latter. Second, oral amino acids affect
the responses of -cells of pancreatic islets, as shown by
the lower suppression of C-peptide. Third, amino acids
preserve several aspects of cognitive responses to hypo-
glycemia, which, to the best of our knowledge, is a novel
ﬁnding.
In type 1 diabetic subjects, the glucagon response to
hypoglycemia with amino acid administration was nearly
similar to the glucagon response to hypoglycemia alone
(without amino acid administration) in the nondiabetic
subjects. Such a result is in line with recent evidence
indicating that the sensitivity of pancreatic -cells to
amino acids is markedly reduced in diabetic subjects
compared with nondiabetic subjects and that a near-
normal glucagon response is seen when the amino acid
alanine is infused in diabetic subjects in hypoglycemia
(13).
Interestingly, the near-normal response of glucagon to
hypoglycemia after oral amino acids observed in the
present study in diabetic subjects is also similar to that
described after ingestion of a mixed meal (15). It is
currently believed that the protein component of the meal
is responsible for such an effect. As reported previously,
the mechanisms of amino acid–induced ampliﬁcation of
the glucagon response to hypoglycemia likely involve both
direct and indirect effects (13). In this study, a direct
stimulatory effect of oral amino acids on glucagon re-
sponse was evident at 60–90 min in both the euglycemic
clamp and the hypoglycemic clamp before hypoglycemia
was established. However, the stimulatory effect of oral
amino acids on glucagon release was modulated by plasma
glucose concentration. It was ampliﬁed by the induction of
hypoglycemia in both nondiabetic and diabetic subjects
but suppressed by euglycemia in both groups of subjects.
This indicates that amino acids directly stimulate glucagon
secretion from the -cell (37) and that hypoglycemia
ampliﬁes the direct stimulatory effect of amino acids on
glucagon release. Furthermore, oral amino acids may also
act through different indirect mechanisms that involve
gastroenteric peptides such as glucagon-like peptide 1 (38)
and a decrease of tonic intra-islet -cell inhibition by
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is possible that the initially greater stimulation of -cell
function by amino acids was followed by a greater decre-
ment in intra-islet insulin concentration during hypoglyce-
mia, resulting in a greater decrease in tonic intra-islet
-cell inhibition by insulin and signaling for increased
glucagon secretion during hypoglycemia in normal non-
diabetic subjects (39). Most likely, the decrement in intra-
islet insulin may be an important factor for the increase in
glucagon secretion during hypoglycemia (40).
The ingestion of amino acids induced a greater peak
response of pancreatic polypeptide compared with pla-
cebo in the hypoglycemic clamp studies in nondiabetic but
not in diabetic subjects. It is well known that pancreatic
polypeptide secretion after ingestion of a mixed meal is
mostly mediated by the vagus nerve or by the extravagal
cholinergic system (41). In addition, hypoglycemia per se
represents a strong stimulus to pancreatic polypeptide
secretion (41). Furthermore, autonomic vagal neuropathy
blunts pancreatic polypeptide response to hypoglycemia
(41). Although the diabetic subjects we studied had no
evident signs of autonomic neuropathy, we cannot ex-
clude the possibility that the lower response of pancreatic
polypeptide concentrations to hypoglycemia in these sub-
jects compared with nondiabetic subjects might be related
to subclinical autonomic neuropathy or to other diabetes-
related causes, including diabetes duration (41).
Elevation of plasma amino acid concentration after
ingestion of amino acids did not affect counterregulatory
hormones, with the exception of glucagon, and symptom-
atic responses to hypoglycemia, whereas the elevation
clearly resulted in preservation of some aspects of cogni-
tive function during hypoglycemia. This is a new ﬁnding
that points toward a net effect of amino acids in supporting
cognition while having no relevant effects on hormonal
and symptomatic responses to hypoglycemia. It should be
noted that previous studies indicate only a partial or no
role of amino acids in sustaining cognition during hypo-
glycemia. In fact, Evans et al. (18) have shown that alanine
infusion can sustain performance of Stroop word and
color tests during hypoglycemia, although a contribution
of elevated lactate levels to performance in those tests
cannot be completely excluded (18). In contrast, M’Bemba
et al. (12) found no effect of infusion of a dipepetide made
of alanine and glutamine on a four-choice reaction time
test. One possible explanation for a speciﬁc effect of
amino acids on cognitive function is that elevated plasma
amino acids do not affect metabolism and neurotransmis-
sion of brain centers that physiologically direct counter-
regulation and symptoms, whereas they may sustain brain
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oration of cognitive function. Therefore, in contrast to the
role of other nonglucose substrates such as lactate (19)
and ketones (20), amino acids limit their effect only to
cognitive function. That would seem advantageous be-
cause the reduced counterregulatory hormone release and
lower symptoms associated with lactate (19) or ketone
(20) use by the brain might weaken defensive responses to
hypoglycemia and generate hypoglycemia unawareness, a
well-known risk factor for severe hypoglycemia (42), even
in the face of preserved cognitive function.
Earlier evidence indicates that amino acids can serve as
energy sources in the brain during insulin-induced hypo-
glycemia (43). Therefore, under such circumstances, they
can be used by neurons and glia cells as an alternative
substrate to glucose to limit the detrimental effect of
glucopenia on cerebral metabolism and function. How-
ever, it has been recently shown that brain amino acid
(alanine and leucine) uptake is not sufﬁcient to offset
energy deﬁcit due to reduced glucose uptake during
hypoglycemia (44) and that increased availability of amino
acids does not result in net brain uptake of amino acids
during hypoglycemia (45). Additionally, several amino
acids such as tryptophan, tyrosine, phenylalanine, histi-
dine, and arginine are used by the brain for the synthesis
of various neurotransmitters and neuromodulators (46)
that play a variety of functions in the brain, including a role
in the regulation of mood state, fatigue, attention, and
memory (47). Therefore, on theoretical grounds, our study
result of preservation of some aspects of cognitive func-
tion during hypoglycemia supplemented with oral amino
acids might be due either to a direct use of amino acids by
neuronal cells to derive energy and maintain cognitive
function or to their conversion to neurotransmitters
and/or neuromodulators able to affect cognition. However,
whichever the mechanism, levels of different classes of
amino acids in the brain depend largely on their availabil-
ity in blood, and when individuals are exposed to stressful
conditions, such as hypoglycemia, brain requirements for
speciﬁc amino acids may be particularly critical. In the
present study, supplementation of oral amino acids not
only prevented the insulin-induced fall in plasma amino
acids observed in the hypoglycemia and placebo studies, it
actually increased the overall concentrations of amino
acids. Likely, these increased concentrations favored
amino acid use by the brain.
The battery of tests that we used assessed a broad range
of cognitve aspects. Overall, amino acid ingestion sus-
tained cognitive domains pertaining to memory, attention,
psychomotor efﬁciency, information processing, and im-
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except immediate memory in diabetic subjects. This inter-
group difference can be most likely attributed either to
diabetes or to a general verbal ability and/or general
intelligence condition. Notably, these results have been
obtained with plasma amino acid concentrations in the
physiological range of the postprandial condition in hu-
mans (	2–3 mmol/l) (15).
Plasma -OH-butyrate concentrations were suppressed
in all studies. However, they were less suppressed after
oral amino acid ingestion in both euglycemia and hypogly-
cemia. Their use by the brain as an alternative substrate to
TABLE 2
Cognitive test scores in 10 nondiabetic and 10 type 1 diabetic subjects studied during clamped hypoglycemia with amino acid and
placebo ingestion and during clamped euglycemia with amino acid ingestion
Nondiabetic subjects Type 1 diabetic subjects
30 min 0 min 160 min P value 30 min 0 min 160 min P value
Nominal
PG (Eu/Hypo) (mg/dl) 90/90 90/90 90/47 90/90 90/90 90/47
Trail-Making part A*
Hypoglycemia-placebo 39  2.6 34  5.0 70  13 0.234 42  5.2 60  9 109  27 0.072
Hypoglycemia–amino acids 36  4.6 36  5.7 65  8.0 32  4.9 68  7.2 63  9.1
Euglycemia–amino acids 30  3.8 67  4.7 61  3.6 39  6.2 65  9.6 78  5.4
Trail-Making part B*
Hypoglycemia-placebo 53  4.9 71  9.4 89  10 0.002 49  2.2 64  9.3 115  26 0.014
Hypoglycemia–amino acids 54  4.1 56  7.6 74  6.6†‡ 52  5.3 63  7.8 69  9.9†
Euglycemia–amino acids 62  6.4 57  6.4 50  2.5† 64  5.6 62  3.5 64  6.7†
PASAT (3 s)§
Hypoglycemia-placebo 59  0.6 58  0.6 41  7.5‡ 0.044 55  0.5 55  0.2 51  1.7‡ 0.031
Hypoglycemia–amino acids 58  0.5 58  0.7 49  3.2‡ 59  1.2 55  0.4 54  1.0‡
Euglycemia–amino acids 52  2.3 54  1.9 57  0.8 53  1.7 54  1.3 58  1.0
PASAT (2 s)§
Hypoglycemia-placebo 47  2.8 52  2.5 33  5.9 0.042 36  1.2 38  3.5 35  3.2‡ 0.038
Hypoglycemia–amino acids 50  2.3 51  3.0 46  2.4† 40  2.8 47  1.7 36  1.6‡
Euglycemia–amino acids 40  3.5 48  3.8 45  2.4† 41  1.5 48  1.2 45  0.8
Digit span forward¶
Hypoglycemia-placebo 4.0  0.3 4.6  0.3 3.3  0.5 0.034 4.2  0.2 5.0  0.3 3.3  0.3‡ 0.028
Hypoglycemia–amino acids 4.3  0.1 4.5  0.2 4.4  0.2† 4.0  0.3 3.8  0.3 3.6  0.2‡
Euglycemia–amino acids 4.3  0.1 4.5  0.1 4.3  0.2† 4.1  0.1 4.2  0.1 4.0  0.1
Digit span reverse¶
Hypoglycemia-placebo 5.0  0.4 4.6  0.4 3.8  0.6‡ 0.038 4.8  0.3 4.7  0.1 4.0  0.3 0.011
Hypoglycemia–amino acids 5.1  0.4 4.4  0.4 4.3  0.5‡ 4.9  0.3 4.5  0.3 4.8  0.2†
Euglycemia–amino acids 4.3  0.6 4.5  0.4 4.8  0.3 4.8  0.2 4.8  0.3 4.5  0.3†
Digit vigilance
Hypoglycemia-placebo 33  2.4 33  2.1 28  3.6 0.149 31  1.2 36  1.2 33  1.1 0.065
Hypoglycemia–amino acids 33  1.4 33  1.9 30  2.5 33  1.4 38  1.4 32  1.0
Euglycemia–amino acids 32  2.1 31  2.7 33  1.5 36  1.4 32  1.3 37  1.5
Verbal ﬂuency**
Hypoglycemia-placebo 9.5  0.5 11.3  0.9 8.2  1.3‡ 0.001 13.5  0.1 12.4  1.0 10.8  0.9‡ 0.002
Hypoglycemia–amino acids 13  0.9 11.4  1.0 9.8  1.1‡ 12.5  0.3 10.8  0.7 9.0  0.6‡
Euglycemia–amino acids 12.3  0.3 11.8  0.6 13.8  0.7 11.0  1.0 12.0  1.4 14.0  1.0
Stroop word††
Hypoglycemia-placebo 94  5.8 104  8.0 80  15.8 0.458 104  4.0 98  3.8 96  1.9‡ 0.014
Hypoglycemia–amino acids 107  7.8 104  7.3 94  8.0 103  1.4 108  1.7 102  1.3‡
Euglycemia–amino acids 98  4.3 103  5.0 104  5.5 106  3.3 109  4.1 114  2.8
Stroop color††
Hypoglycemia-placebo 73  3.2 82  3.4 55  10 0.066 78  2.5 79  2.9 59  0.8 0.002
Hypoglycemia–amino acids 78  4.1 79  2.7 69  3.8 76  0.9 77  1.7 75  2.3†‡
Euglycemia–amino acids 74  1.2 79  3.1 79  1.1 81  2.5 83  2.5 87  1.9
Stroop color-words††
Hypoglycemia-placebo 51  2.3 55  1.3 38  6.8 0.025 48  1.7 52  0.9 50  0.4‡ 0.042
Hypoglycemia–amino acids 62  3.2 59  2.0 51  2.0†‡ 49  0.5 50  1.7 49  1.6‡
Euglycemia–amino acids 56  2.6 55  2.2 60  3.2 46  2.1 53  1.5 60  1.7
Verbal memory test‡‡
Hypoglycemia-placebo 4.8  0.1 3.6  0.6 2.2  0.7 0.042 5.0  0.0 5.0  0.0 3.5  0.4‡ 0.015
Hypoglycemia–amino acids 4.3  0.2 4.2  0.3 3.4  0.5† 5.0  0.0 4.8  0.1 4.0  0.3‡
Euglycemia–amino acids 4.2  0.2 4.0  0.4 3.2  0.5† 4.8  0.1 4.8  0.1 4.5  0.2
Data are means  SE. P values are calculated from repeated-measures ANOVA. †P  0.05 vs. hypoglycemia-placebo. ‡P  0.05 vs.
euglycemia–amino acids. *Time(s) required to complete the task. §Number of correct responses. ¶Number of digit sequences correctly
repeated. Number of correct targets crossed out in 90 s. **Number of words named in 60 s. ††Number of correct responses in 45 s. ‡‡Number
of words recalled.
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DIABETES, VOL. 57, JULY 2008 1915sustain brain metabolism and function during hypoglyce-
mia cannot be completely excluded. However, this is
unlikely because, ﬁrst, the levels of -OH-butyrate in our
study were much lower than those that have been shown
to be effective in maintaining cognitive function during
hypoglycemia in previous studies (20), and second, -OH-
butyrate diminished counterregulatory and symptomatic
responses to hypoglycemia in those studies (20) but not in
our present study.
In conclusion, the present study indicates that oral
amino acids improve some aspects of cognitive function in
response to hypoglycemia and potentiate (in nondiabetic
subjects) and recover (in subjects with type 1 diabetes)
responses of glucagon to hypoglycemia. Additional studies
are required to prove that these beneﬁcial effects of oral
amino acids during hypoglycemia translate into clinical
advantages for people with type 1 diabetes and to possibly
demonstrate that they contribute to reduction of the risk
of severe hypoglycemia in type 1 diabetes.
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